This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
1.PK Dewan , Inhalational anthrax outbreak among postal workers, Washington, DC, 2001. Emerging Infectious Diseases 2002; 8: 1066–1072.
2.JH Bell , E Fee , TM Brown . Anthrax and the wool trade. 1902. American Journal of Public Health 2002; 92: 754–757.
3.PS Brachman , FR Fekety . Industrial anthrax. Annals of the New York Academy of Sciences 1958; 70: 574–584.
4.ME Bales , Epidemiologic response to anthrax outbreaks: field investigations, 1950–2001. Emerging Infectious Diseases 2002; 8: 1163–1174.
7.N Metcalfe . The history of woolsorters' disease: a Yorkshire beginning with an international future? Occupational Medicine 2004; 54: 489–493.
12.DL Doolan , The US capitol bioterrorism anthrax exposures: clinical epidemiological and immunological characteristics. Journal of Infectious Diseases 2007; 195: 174–184.
13.P Wattiau , Occurrence and genetic diversity of Bacillus anthracis strains isolated in an active wool-cleaning factory. Applied and Environmental Microbiology 2008; 74: 4005–4011.
14.P Wattiau , Immunologic response of unvaccinated workers exposed to anthrax, Belgium. Emerging Infectious Diseases 2009; 15: 1637–1640.
15.RE Biagini , Determination of serum IgG antibodies to Bacillus anthracis protective antigen in environmental sampling workers using a fluorescent covalent microsphere immunoassay. Occupational and Environmental Medicine 2004; 61: 703–708.
16.JL Hadler . Learning from the 2001 anthrax attacks: immunological characteristics. The Journal of Infectious Diseases 2007; 195: 163–164.
18.KP Fennelly , Airborne infection with Bacillus anthracis – from mills to mail. Emerging Infectious Diseases 2004; 10: 996–1002.
20.WT Sanderson , Bacillus anthracis contamination and inhalational anthrax in a mail processing and distribution center. Journal of Applied Microbiology 2004; 96: 1048–1056.
21.R Grunow , Monitoring of ELISA-reactive antibodies against anthrax protective antigen (PA), lethal factor (LF), and toxin-neutralising antibodies in serum of individuals vaccinated against anthrax with the PA-based UK anthrax vaccine. Vaccine 2007; 25: 3679–3683.
22.CP Quinn , Immune responses to Bacillus anthracis protective antigen in patients with bioterrorism-related cutaneous or inhalation anthrax. Journal of Infectious Diseases 2004; 190: 1228–1236.
23.N Abboud , A Casadevall . Immunogenicity of Bacillus anthracis protective antigen domains and efficacy of elicited antibody responses depend on host genetic background. Clinical and Vaccine Immunology 2008; 15: 1115–1123.
24.MN Swartz . Recognition and management of anthrax – an update. New England Journal of Medicine 2001; 345: 1621–1626.
25.E Van den Enden , A Van Gompel , M Van Esbroeck . Cutaneous anthrax, Belgian traveler. Emerging Infectious Diseases 2006; 12: 523–525.